Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum]

Thorlund K, Druyts E, Aviña-Zubieta JA, et al. Biologics: Targets and Therapy. 2012;6:417-427. On page 418, note that under Search strategy, Merck-Shire-Dome should have been listed as Merck, Sharp, and Dohme.On page 421, Figure 2, the relative risk for golimumab versus placebo for the PsARC respons...

Full description

Saved in:
Bibliographic Details
Published in:Biologics 2014-01, Vol.8 (default), p.57-58
Main Authors: Thorlund, K, Druyts, E, Avina-Zubieta, J.A
Format: Article
Language:English
Subjects:
Arthritis
Corrigendum
Psoriatic arthritis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thorlund K, Druyts E, Aviña-Zubieta JA, et al. Biologics: Targets and Therapy. 2012;6:417-427. On page 418, note that under Search strategy, Merck-Shire-Dome should have been listed as Merck, Sharp, and Dohme.On page 421, Figure 2, the relative risk for golimumab versus placebo for the PsARC response was incorrectly listed as 2.45, and should be 3.45. The mean difference for etanercept versus placebo for the PASI response was incorrectly listed as 2.13, and should be 3.13. The x-axis of the PASI forest plot was incorrectly labeled with mean difference values of 1, 2, 3 and 4. The correct values are 3, 6, 9 and 12.Read the original article
ISSN:1177-5475
1177-5475
1177-5491
DOI:10.2147/BTT.S61099